Evaluation of circulating ADH and MIC-1 as diagnostic markers in Egyptian patients with pancreatic cancer

dc.AffiliationOctober University for modern sciences and Arts (MSA)
dc.contributor.authorMohamed A.A.
dc.contributor.authorSoliman H.
dc.contributor.authorIsmail M.
dc.contributor.authorZiada D.
dc.contributor.authorFarid T.M.
dc.contributor.authorAref A.M.
dc.contributor.authorAl Daly M.E.
dc.contributor.authorAbd Elmageed Z.Y.
dc.contributor.otherDepartments of Biochemistry
dc.contributor.otherNational Hepatology and Tropical Medicine Research Institute
dc.contributor.otherEgypt; Department of Tropical Medicine and Infectious Diseases
dc.contributor.otherFaculty of Medicine
dc.contributor.otherTanta University
dc.contributor.otherEgypt; Departments of Surgery
dc.contributor.otherNational Hepatology and Tropical Medicine Research Institute
dc.contributor.otherEgypt; Department of Clinical Biochemistry
dc.contributor.otherFaculty of Medicine
dc.contributor.otherKing Abdel Aziz University
dc.contributor.otherJeddah
dc.contributor.otherSaudi Arabia; Department of Biological Sciences
dc.contributor.otherFaculty of Dentistry
dc.contributor.otherModern Science and Arts University
dc.contributor.otherEgypt; Clinical Oncology
dc.contributor.otherFaculty of Medicine
dc.contributor.otherCairo University
dc.contributor.otherEgypt; Tulane University Health Sciences Center
dc.contributor.otherTulane University School of Medicine
dc.contributor.other1430 Tulane Ave
dc.contributor.otherNew Orleans
dc.contributor.otherLA
dc.contributor.otherUnited States
dc.date.accessioned2020-01-09T20:42:03Z
dc.date.available2020-01-09T20:42:03Z
dc.date.issued2015
dc.descriptionScopus
dc.descriptionMSA Google Scholar
dc.description.abstractBackground Despite the incidence rate of pancreatic cancer (PC) is uncommon in developing countries, it is considered as one of the most lethal disease. Improving patients' survival requires diagnosis of the disease at early stage. Therefore, it is imperative to identify more specific and sensitive marker(s) to be used for early detection of PC. Objectives Our aim is to evaluate the potential role of circulating ADH and MIC-1 to be used as diagnostic markers in Egyptian patients and assess their value either alone or combined with CA19-9 in early detection of PC. Methods Alcohol dehydrogenase (ADH), macrophage inhibitory cytokine (MIC-1) and CA19-9 were measured by ELISA in serum procured from PC patients (n = 50) versus normal subjects (n = 20). Results Our results demonstrate that the circulating levels of ADH, MIC-1 and CA19-9 in blood of PC were significantly higher than in healthy controls (HCs) (p < 0.001). The highest marker sensitivity observed at early stage was MIC-1 (90%) and specificity was ADH (83%). The level of all three markers was elevated significantly in early stage of PC in comparison to HCs. The addition of ADH and MIC-1 to CA19-9 significantly improved the efficacy of diagnosis (p = 0.023). Conclusion Our data demonstrate that not only the combination of ADH and MIC-1 to CA19-9 can be used in early detection of PC but also can improve the overall quality of diagnosis of this lethal disease. � 2014 IAP and EPC.en_US
dc.identifier.doihttps://doi.org/10.1016/j.pan.2014.10.008
dc.identifier.doiPubMedID25464937
dc.identifier.issn14243903
dc.identifier.otherhttps://doi.org/10.1016/j.pan.2014.10.008
dc.identifier.otherPubMedID25464937
dc.identifier.urihttps://t.ly/1VVKE
dc.language.isoEnglishen_US
dc.publisherElsevieren_US
dc.relation.ispartofseriesPancreatology
dc.relation.ispartofseries15
dc.subjectOctober University for Modern Sciences and Arts
dc.subjectجامعة أكتوبر للعلوم الحديثة والآداب
dc.subjectUniversity of Modern Sciences and Arts
dc.subjectMSA University
dc.subjectADH MIC-1en_US
dc.subjectCA19-9en_US
dc.subjectDiagnostic markersen_US
dc.subjectPancreatic canceren_US
dc.subjectSpecificity and sensitivityen_US
dc.subjectalanine aminotransferaseen_US
dc.subjectalbuminen_US
dc.subjectalcohol dehydrogenaseen_US
dc.subjectaspartate aminotransferaseen_US
dc.subjectbilirubin glucuronideen_US
dc.subjectCA 19-9 antigenen_US
dc.subjectgamma glutamyltransferaseen_US
dc.subjectglucoseen_US
dc.subjectgrowth differentiation factor 15en_US
dc.subjecttumor markeren_US
dc.subjectvasopressinen_US
dc.subjectalcohol dehydrogenaseen_US
dc.subjectCA 19-9 antigenen_US
dc.subjectGDF15 protein, humanen_US
dc.subjectgrowth differentiation factor 15en_US
dc.subjecttumor markeren_US
dc.subjectadulten_US
dc.subjectageden_US
dc.subjectArticleen_US
dc.subjectblood analysisen_US
dc.subjectcancer diagnosisen_US
dc.subjectcancer growthen_US
dc.subjectcancer stagingen_US
dc.subjectclinical articleen_US
dc.subjectcontrolled studyen_US
dc.subjectcross-sectional studyen_US
dc.subjectdiagnostic accuracyen_US
dc.subjectdiagnostic test accuracy studyen_US
dc.subjectdiagnostic valueen_US
dc.subjectearly diagnosisen_US
dc.subjectEgyptianen_US
dc.subjectenzyme activityen_US
dc.subjectenzyme linked immunosorbent assayen_US
dc.subjectfemaleen_US
dc.subjectfollow upen_US
dc.subjectglucose blood levelen_US
dc.subjectgold standarden_US
dc.subjecthumanen_US
dc.subjectinternational normalized ratioen_US
dc.subjectmaleen_US
dc.subjectpancreas canceren_US
dc.subjectpredictive valueen_US
dc.subjectpriority journalen_US
dc.subjectprotein blood levelen_US
dc.subjectprothrombin timeen_US
dc.subjectsensitivity and specificityen_US
dc.subjectvasopressin blood levelen_US
dc.subjectblooden_US
dc.subjectcase control studyen_US
dc.subjectclinical trialen_US
dc.subjectEgypten_US
dc.subjectmiddle ageden_US
dc.subjectPancreatic Neoplasmsen_US
dc.subjectvery elderlyen_US
dc.subjectAgeden_US
dc.subjectAged, 80 and overen_US
dc.subjectAlcohol Dehydrogenaseen_US
dc.subjectCA-19-9 Antigenen_US
dc.subjectCase-Control Studiesen_US
dc.subjectCross-Sectional Studiesen_US
dc.subjectEgypten_US
dc.subjectEnzyme-Linked Immunosorbent Assayen_US
dc.subjectFemaleen_US
dc.subjectGrowth Differentiation Factor 15en_US
dc.subjectHumansen_US
dc.subjectMaleen_US
dc.subjectMiddle Ageden_US
dc.subjectPancreatic Neoplasmsen_US
dc.subjectSensitivity and Specificityen_US
dc.subjectTumor Markers, Biologicalen_US
dc.titleEvaluation of circulating ADH and MIC-1 as diagnostic markers in Egyptian patients with pancreatic canceren_US
dc.typeArticleen_US
dcterms.isReferencedBySoliman, A.S., Zhang, Q., Saleh, T., Zarzour, A., Selim, M., Abdel-Fattah, M., Pancreatic cancer mortality in Egypt: Comparison to the United States pancreatic cancer mortality rates (2006) Cancer Detect Prev, 30 (5), pp. 473-479. , Epub 2006/10/28; Jemal, A., Murray, T., Ward, E., Samuels, A., Tiwari, R.C., Ghafoor, A., Cancer statistics, 2005 (2005) CA Cancer J Clin, 55 (1), pp. 10-30. , Epub 2005/01/22; Poruk, K.E., Firpo, M.A., Adler, D.G., Mulvihill, S.J., Screening for pancreatic cancer: Why, how, and who? (2012) Ann Surg, 257 (1), pp. 17-26. , Epub 2012/08/17; Brand, R., The diagnosis of pancreatic cancer (2001) Cancer J, 7 (4), pp. 287-297. , Epub 2001/09/20; Duraker, N., Hot, S., Polat, Y., Hobek, A., Gencler, N., Urhan, N., CEA, CA 19-9, and CA 125 in the differential diagnosis of benign and malignant pancreatic diseases with or without jaundice (2007) J Surg Oncol, 95 (2), pp. 142-147. , Epub 2007/01/31; Harsha, H.C., Kandasamy, K., Ranganathan, P., Rani, S., Ramabadran, S., Gollapudi, S., A compendium of potential biomarkers of pancreatic cancer (2009) PLoS Med, 6 (4), p. e1000046. , Epub 2009/04/11; Grantzdorffer, I., Carl-Mcgrath, S., Ebert, M.P., Rocken, C., Proteomics of pancreatic cancer (2008) Pancreas, 36 (4), pp. 329-336. , Epub 2008/04/26; Locker, G.Y., Hamilton, S., Harris, J., Jessup, J.M., Kemeny, N., MacDonald, J.S., ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer (2006) J Clin Oncol, 24 (33), pp. 5313-5327. , Epub 2006/10/25; Chrostek, L., Jelski, W., Szmitkowski, M., Puchalski, Z., Alcohol dehydrogenase (ADH) isoenzymes and aldehyde dehydrogenase (ALDH) activity in the human pancreas (2003) Dig Dis Sci, 48 (7), pp. 1230-1233. , Epub 2003/07/23; Riveros-Rosas, H., Julian-Sanchez, A., Pina, E., Enzymology of ethanol and acetaldehyde metabolism in mammals (1997) Arch Med Res, 28 (4), pp. 453-471. , Epub 1997/01/01; Jelski, W., Kutylowska, E., Laniewska-Dunaj, M., Orywal, K., Laszewicz, W., Szmitkowski, M., Alcohol dehydrogenase (ADH) isoenzymes and aldehyde dehydrogenase (ALDH) activity in the sera of patients with acute and chronic pancreatitis (2011) Exp Mol Pathol, 91 (2), pp. 631-635. , Epub 2011/07/30; Jelski, W., Kutylowska, E., Laniewska-Dunaj, M., Szmitkowski, M., Alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH) as candidates for tumor markers in patients with pancreatic cancer (2011) J Gastrointestin Liver Dis, 20 (3), pp. 255-259. , Epub 2011/10/01; Bootcov, M.R., Bauskin, A.R., Valenzuela, S.M., Moore, A.G., Bansal, M., He, X.Y., MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily (1997) Proc Natl Acad Sci U S A, 94 (21), pp. 11514-11519. , Epub 1997/10/23; Koopmann, J., Buckhaults, P., Brown, D.A., Zahurak, M.L., Sato, N., Fukushima, N., Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers (2004) Clin Cancer Res, 10 (7), pp. 2386-2392. , Epub 2004/04/10; Ozkan, H., Demirbas, S., Ibis, M., Akbal, E., Koklu, S., Diagnostic validity of serum macrophage inhibitor cytokine and tissue polypeptide-specific antigen in pancreatobiliary diseases (2011) Pancreatology, 11 (3), pp. 295-300. , Epub 2011/07/16; Misek, D.E., Patwa, T.H., Lubman, D.M., Simeone, D.M., Early detection and biomarkers in pancreatic cancer (2007) J Natl Compr Canc Netw, 5 (10), pp. 1034-1041. , Epub 2007/12/07; Kaur, S., Chakraborty, S., Baine, M.J., Mallya, K., Smith, L.M., Sasson, A., Potentials of plasma NGAL and MIC-1 as biomarker(s) in the diagnosis of lethal pancreatic cancer (2013) PLoS One, 8 (2), p. e55171. , Epub 2013/02/06; Ballehaninna, U.K., Chamberlain, R.S., Biomarkers for pancreatic cancer: Promising new markers and options beyond CA 19-9 (2013) Tumour Biol, 34 (6), pp. 3279-3292. , Epub 2013/08/21; Buxbaum, J.L., Eloubeidi, M.A., Molecular and clinical markers of pancreas cancer (2010) JOP, 11 (6), pp. 536-544. , Epub 2010/11/12; Kim, T.H., Han, S.S., Park, S.J., Lee, W.J., Woo, S.M., Yoo, T., CA 19-9 level as indicator of early distant metastasis and therapeutic selection in resected pancreatic cancer (2010) Int J Radiat Oncol Biol Phys, 81 (5), pp. e743-e748. , Epub 2010/12/07; Jelski, W., Zalewski, B., Szmitkowski, M., Alcohol dehydrogenase (ADH) isoenzymes and aldehyde dehydrogenase (ALDH) activity in the sera of patients with pancreatic cancer (2008) Dig Dis Sci, 53 (8), pp. 2276-2280. , Epub 2007/12/21; Goggins, M., Molecular markers of early pancreatic cancer (2005) J Clin Oncol, 23 (20), pp. 4524-4531. , Epub 2005/07/09
dcterms.sourceScopus

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
avatar_scholar_256.png
Size:
6.31 KB
Format:
Portable Network Graphics
Description: